Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At $3.52, my theory that the change of CEO, would cause a
turning point, is duly proven.
Dubi
>>and Compugen (CGEN.O: Quote, Profile, Research)<<
U.S. Venture Partners eyes Israel hi-tech firms
Wed Jul 20, 2005 11:38 AM ET
By Steven Scheer
TEL AVIV, July 20 (Reuters) - U.S. Venture Partners (USVP) plans to invest in a number of Israeli high-tech start-ups using some of the $600 million in its latest venture capital fund, a USVP general partner said on Wednesday.
"Of the $600 million, we expect a meaningful percentage -- a double digit percentage -- allocated to Israel," Chris Rust told reporters during a visit to Tel Aviv. "We have 18 to 20 active (Israeli) investment proposals ... and I am sure some of those will crossover."
He said USVP is particularly focused on early-stage funding for companies in life sciences, medical devices, semiconductors, software, clean technology, security and telecommunications, sectors heavily represented in Israel. Rust said California-based USVP targets companies with the potential to go public.
Overall, USVP's ninth fund since its establishment in 1981 aims to comprise 55 to 65 companies, mostly in Silicon Valley and Israel, said Rust, noting an average financing round is $4 million, with $8 million the most it invests at one time. It often invests with other funds.
He noted that over the past 24 years, USVP has invested $2.5 billion in high-tech companies, usually taking a 20 to 30 percent stake.
USVP has invested $100 million in Israeli companies over the last decade, including early stage funding in Check Point Software Technologies (CHKP.O: Quote, Profile, Research) and Compugen (CGEN.O: Quote, Profile, Research) .
In recent years, USVP has invested in Dotomi, an Internet advertising management firm, as well as chip maker Mellanox, software maker Imperva and broadband access systems maker Actelis.
"We are drawn to Israel; it has tremendous resources on the people side," Rust said, downplaying an often troublesome security environment, particularly over the past five years of Palestinian-Israeli violence.
"We take a long-term view," he said. "We are not deterred from investing in Israel ... These are issues the whole world is grappling with. Israelis are resilient and productive even when faced with these complexities."
He pointed to similarities between the cultures of the U.S. and Israel, as well as a democratic political system and free markets.
Rust said that although many funds were shifting their focus to hot-spots like China and India, USVP does not plan on significant investments there, despite the fact that China produces more engineer graduates than the rest of the world.
"We expect there to be continued globalisation and competition to the United States and Israel from emerging markets like India and China," he said.
http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh17920_2005-07-20_15-38-08_l20....
Dubi
Compugen Earnings Conference Call (Q2 2005)
Scheduled to start Wed, Jul 27, 2005, 10:00 am Eastern
http://biz.yahoo.com/cc/1/58071.html
Dubi
Compugen has been selected together with ECI, Motorola Israel, and Gilat to participate in projects totalling 20 million euros in funding. Six Israeli companies have been selected from among a group of 44 who submitted requests. A total of 53 Israeli companies have pasted the inital qualification stage from among 173 applications and more grants are expected in the future.
Each of the recepients will be teamed with European companies and will be funded for 1-2 million euros.
http://tinyurl.com/9erx2
Dubi
>>>One of the leading projects, between Israeli Compugen and Ortho-Clinical Diagnostics, a J&J subsidiary, is for discovery and development of markers for the diagnosis of several cancers and of congestive heart failure.<<<
"Among the participating Israeli companies there are quite a few cutting edge companies such as Cima Nanotech, Compugen, Ceragon, Discretix, Elbit Systems, Visionix, Nexense, Wisair and others."
http://www.globes.co.il/serveen/globes/docview.asp?did=928048&fid=942
Dubi
Among some of CGEN holders are,
http://leumitrade-il.bankleumi.co.il/LTI/Info/Companies/Holders.asp
TEVA, via various holders, including E.Hurvitz personally,
For me some valueable 'KOSHER' stamp.
Dubi
Global biotech delegation in Israel next week
The major investment houses will seek Israeli opportunities, while the large biotechnology companies will examine possibilities for cooperation.
Batya Feldman 23 Jun 05 19:36
A delegation comprising some of the most senior figures in the global biotechnology industry and financiers in the field will visit Israel next week.
Among the delegation's members will be Harlan Weissman, who is executive vice president, research and development at Johnson & Johnson; James Boylan, director of medical investment at Merrill Lynch; Marina Bozilenko, a senior managing director in the Investment Banking Division of Bear Stearns; acting commissioner of the US Food and Drug Administration (FDA) Dr. Lester M. Crawford; James Henderson, manager of the health group at HSBC; Michael Vasinkevich, a principal and senior managing director at Rodman & Renshaw; Citigroup Health Care Group managing director Mark Simon; and senior representatives of the specialist venture capital firms OrbiMed, Polaris, Prospect, and others.
Irwin Katsof of Global Capital Associates, which is organizing the delegation, said yesterday that the that its aim was to enable senior people to meet Israeli biotechnology companies. The investment houses represented on the delegation seek to examine investments in Israeli companies, while the large biotechnology companies want to examine the possibilities for cooperation with the Israeli companies.
Katsof, who was formerly former executive director of The Jerusalem Fund of Aish HaTorah, an organization that promotes awareness of Judaism around the world, has considerable experience in organizing business delegations to Israel. AOL's large investment in Shopping.com a few years ago resulted from a meeting Katsof arranged between an Israeli group and US investors.
From his office in Times Square in New York, Katsof said, "Global Capital operates globally - in New York, Washington, Israel, and Moscow. As a business, we want to build partnerships between Israel and American companies. Last May, a smaller delegation visited Israel, following which Vision Science received a $10 million PIPE (private investment in public equity) investment from Rodman Renshaw. This time, the delegation is larger, with representation from senior levels in the industry."
Katsof said a high-tech delegation with a similar make-up would visit in September, with senior representatives from Warner Brothers, Applied Materials, Nextel, Deutsche Bank, IBM, and other companies. Two further delegations, in the areas of medical devices and defense, are planned.
Members of the delegation will meet with representatives of companies and local venture capital funds, including Atox Bio, Cell-Cure, Compugen, CorAssist, Cardiovascular, CureTech, Gamida-Cell, Glucon Medical, HealOr, Kamada, MonaLiza Medical, Nanopharma, NeuroTrax, ObeCure, OrSense, Pharmos, Procognia, Proneuron Biotechnologies, Protalix Biotherapeutics, QuantomiX, Rad-BioMed Incubator, Sol-Gel Technologies, SuperDimension, Syneron Medical, UltraShape, and Vecta.
Published by Globes [online], Israel business news - www.globes.co.il - on Thursday, June 23, 2005
Dubi
CGEN, is dually traded, TASE being the volume
and market price leader.
Today, Sunday, price is up, closing arbitrage
gap with CGEN/Naz.
Dubi
At this price level, indeed made my entry.
My expectations from the new CEO are high.
CGEN will see brigher days.
Dubi
Presenting Companies
Confirmed Companies:
Atox Bio Inc.
Cell-Cure, Ltd
Compugen, Ltd
CorAssist Cardiovascular Ltd.
CureTech, Ltd.
Gamida-Cell Ltd.
Glucon Medical Ltd.
HealOr Ltd.
Kamada Ltd.
MonaLiza Medical Ltd.
Nanopharma Inc.
NeuroTrax Corp.
ObeCure
OrSense Ltd.
Pharmos Ltd.
Procognia Ltd.
Proneuron Biotechnologies, Inc.
Protalix Biotherapeutics Ltd.
QuantomiX Ltd.
Rad-BioMed Incubator Ltd.
Sol-Gel Technologies Ltd.
superDimension Ltd.
Syneron Medical Ltd.
UltraShape Inc.
Vecta Ltd.
http://www.globalcapitalassociates.com/ls/presenting/index.php
Dubi
Tue: Compugen in tailspin, needs help
Compugen’s steep fall in revenue, larger loss, and drop in cash reserves are a deadly combination, but the right strategic partnerships could save the company, which still has plenty of cash.
Shlomo Greenberg
Compugen (Nasdaq: CGEN; TASE: CGEN) has been on an alarming slide since February, and closed yesterday’s trading below $3. The share has already lost 55% of its value, and appears to be on a lengthy downtrend. Since none of its shareholders expected a big profit on their investment in the near future, or at least I hope they didn’t, the reason for the plunge in the share that appears likely to me is a combination of exhaustion and concern. Investors are concerned about the fall in the share on the one hand, and on the other than the company’s report indicates that it is liable to encounter a crisis before it can achieve its goals. Incidentally, these feelings do not exist for Keryx Biopharmaceuticals (Nasdaq: KERX; LSE: KRX). For various reasons, mostly having to do with the company’s management, Keryx’s investors feel more confident.
Compugen reported a steep fall in revenue, a bigger loss, and a $5 million drop in cash reserves in the first quarter. In this industry, this is a deadly combination. I’ve been saying for a long time that companies like Compugen must sooner or later find a patron in order to guarantee a source for the cash that they will need in the future. Compugen already has several strategic partnerships, but what it needs are partners with financing, according to the model exemplified by Millennium Pharmaceuticals (Nasdaq: MLNM). Millennium is a partner of all the leading companies, from Pfizer (NYSE: PFE; LSE: PFZ) to Amgen (Nasdaq: AMGN), all of which contributed to it. A partnership like this will significantly allay the fears of investors who would like to buy genomic shares, but are worried that the money will run out.
Personally, it doesn’t seem to me that Compugen has any real survival worries. They still have enough cash, and they are in the hot and growing genome field. Compugen’s platform is interesting and important, and it all depends now on management’s ability to form strategic partnerships. For speculators and those with endurance, the current share price is probably an opportunity, because a company value of $83 million, when the company has over half of that in the bank, certainly looks interesting.
Savient Pharmaceuticals (Nasdaq: SVNT) is on the way up, which is what I expected. Obviously, the main reasons for its steep rise are its change in management, and its value. For example, is Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) getting interested again in Savient’s biologics division (which used to be Biotechnology General)? We’ll have to wait and see what happens here.
Published by Globes [online] - www.globes.co.il - on June 21, 2005
The above recommendations were made by a person/s working in the investment industry who may hold positions in securities mentioned in the column. This column should not be taken as advice to buy, sell or continue to hold any securities, and anyone acting on the advice of this column does so at his or her own risk.
Dubi
Compugen and Biosite Announce Diagnostic Collaboration
Monday June 20, 7:00 am ET
TEL AVIV, Israel & SAN DIEGO--(BUSINESS WIRE)--June 20, 2005--Compugen Ltd. (Nasdaq:CGEN - News) and Biosite® Incorporated (Nasdaq:BSTE - News) announced today a collaboration for the development and commercialization of diagnostic products. Under the agreement, Biosite is licensed to develop and commercialize immunoassay based diagnostic products using novel biomarkers discovered by Compugen. Using its genomic platform and other proprietary computational tools, Compugen is expected to provide Biosite with comprehensive data on several gene targets to be nominated by Biosite.
ADVERTISEMENT
Under the terms of the agreement, Compugen grants to Biosite an exclusive license to use the selected Compugen targets for immunoassay based diagnostic applications. In return, Compugen is to receive milestone payments and royalties from the sales of each diagnostic product emerging from the collaboration. Compugen retains the exclusive right to pursue further development in the therapeutic field and Biosite will be entitled to receive from Compugen milestone payments and royalties arising from any successful therapeutic application.
The collaboration combines Biosite's expertise in rapid, high-affinity antibody development and successful commercialization of proprietary testing platforms consisting of both individual diagnostic markers and panels of markers with Compugen's unique discovery capabilities. Compugen's discovery process relies on the comprehensive predictive analysis of the human proteome provided by the Company's genomic platform. The result of this analysis is utilized with a variety of discovery engines, each designed to identify novel proteins with specific characteristics from the vast numbers predicted by the discovery process.
"We are looking forward to working in collaboration with Compugen," said Gunars Valkirs, Ph.D., Biosite's Senior Vice President, Discovery. "We hope that this partnership will enable access to novel markers in areas of strategic focus to Biosite that will lead to new product opportunities for us."
Mor Amitai, President and Chief Executive Officer of Compugen, said, "We are excited about the opportunity to collaborate with Biosite, a leading provider of rapid diagnostic products and antibody development technologies. This agreement marks Compugen's third diagnostic collaboration in less than a year, which we believe positions us as a leader in discovery of biomarker candidates. Our activities in diagnostic discovery complement our internal drug discovery efforts."
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing proteomics discoveries for the advancement of medical diagnosis. The Company's products contribute to improvements in medical care by aiding physicians in the diagnosis of critical diseases and health conditions. Biosite's Triage® rapid diagnostics are used in approximately 50 percent of U.S. hospitals and in over 50 international markets. Information on Biosite can be found at www.biosite.com.
About Compugen
Compugen is a drug and diagnostic discovery company incorporating ideas and methods from mathematics, computer science, and physics into biology, chemistry, and medicine. The Company's powerful predictive models and discovery engines are both advancing the understanding of important biological phenomena and enabling the discovery of numerous potential therapeutic products and diagnostic markers. The Company has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the Company; additional discoveries have been out-licensed for development. Among Compugen's customers and partners are leading pharmaceutical and diagnostic companies, such as Abbott Laboratories, Diagnostic Products Corporation, Novartis, and Pfizer. Compugen has established a small-molecule drug discovery affiliate - Keddem Bioscience, and an agricultural biotechnology affiliate - Evogene. For additional information, please visit Compugen's corporate Website at www.cgen.com.
Dubi
Compugen to Present at the BIO 2005 Annual International Convention
Thursday June 16, 8:49 am ET
TEL AVIV, Israel--(BUSINESS WIRE)--June 16, 2005--Compugen Ltd. (NASDAQ: CGEN - News) announced today that representatives of the Company are scheduled to present in two sessions at the BIO 2005 Annual International Convention in Philadelphia, PA. Martin Gerstel, Compugen's Chairman of the Board will chair a session titled "Life Science is from Venus, the Financial Community is from Mars: Part Two" on Monday, June 20 at 4:00 PM Eastern Daylight Time. Salomon Langer, M.D., Senior Vice President, Drug Discovery will chair a session in the drug discovery and development track titled "Discovery Engines and Other Strategies to Improve Productivity of Drug Discovery" on Tuesday, June 21 at 4:00 PM Eastern Daylight Time.
About Compugen
Compugen is a drug and diagnostic discovery company incorporating ideas and methods from mathematics, computer science, and physics into biology, chemistry and medicine. The Company's powerful predictive models and discovery engines are both advancing the understanding of important biological phenomena and enabling the discovery of numerous potential therapeutic products and diagnostic markers. The Company has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the Company; additional discoveries have been out-licensed for development. Among Compugen's customers and partners are leading pharmaceutical and diagnostic companies, such as Abbott Laboratories, Diagnostic Products Corporation, Novartis, and Pfizer. Compugen has established a small-molecule drug discovery affiliate - Keddem Bioscience, and an agricultural biotechnology affiliate - Evogene. For additional information, please visit Compugen's corporate Website at www.cgen.com.
--------------------------------------------------------------------------------
Contact:
Compugen:
Director, Corporate Communications
Tsipi Haitovsky, +972-52-5989892
tsipi@cgen.com
or
The Ruth Group:
investors:
John Quirk, 646-536-7029
jquirk@theruthgroup.com
or
media:
Zack Kubow, 646-536-7020
zkubow@theruthgroup.com
--------------------------------------------------------------------------------
Source: Compugen Ltd.
Dubi
CGEN at under $3 will represent a good entry point.
FWIW, JMHO
Dubi
Compugen signs deal with Johnson & Johnson co
The collaboration combines Compugen's discovery capability with Ortho-Clinical Diagnostic's commercialization strengths.
Globes correspondent 8 Jun 05 15:20
Compugen (Nasdaq: CGEN; TASE: CGEN) announced today a collaboration agreement with Ortho-Clinical Diagnostics, a Johnson & Johnson company, for the development and commercialization of immunoassay diagnostic markers.
Under the agreement, Ortho-Clinical Diagnostics and Compugen will jointly develop diagnostic products based on biomarkers discovered by Compugen. Ortho-Clinical Diagnostics will have worldwide rights for commercialization, with Compugen receiving development milestones and royalties.
During the initial phase of the agreement, Ortho-Clinical Diagnostics will have the right to select up to nine biomarkers for development from Compugen's continuously growing portfolio, with the parties then collaborating on the initial clinical validation of the selected biomarkers.
Under the agreement, successfully validated biomarkers will be developed into products and commercialized by Ortho-Clinical Diagnostics, with Compugen receiving milestone payments and license fees for each commercialized biomarker, in addition to revenue-based royalties.
Compugen stated that the collaboration combined its discovery capability and existing candidate portfolio with Ortho-Clinical Diagnostic's global development and commercialization strengths. Compugen president and CEO Mor Amitai called the agreement "an important commercialization opportunity."
Compugen is a drug and diagnostic discovery company incorporating ideas and methods from mathematics, computer science, and physics into biology, chemistry, and medicine. Compugen's discovery process relies on the comprehensive predictive analysis of the human proteome provided by the company's LEADS platform. The results of this analysis are utilized with a variety of discovery engines, each designed to identify novel proteins with specific desired characteristics from the vast number predicted by the discovery process.
The company has an early stage in-house pipeline consisting of selected therapeutic protein candidates which it has discovered; additional discoveries have been out-licensed for development.
Among Compugen's customers and partners are leading pharmaceutical and diagnostic companies, such as Abbott Laboratories, Diagnostic Products Corporation, Novartis, and Pfizer. Compugen has established a small-molecule drug discovery affiliate, called Keddem Bioscience, and an agricultural biotechnology affiliate, called Evogene.
Published by Globes [online], Israel business news - www.globes.co.il - on Wednesday, June 08, 2005
Dubi
Compugen Announces Diagnostic Biomarker Collaboration
Wednesday June 8, 7:00 am ET
Compugen and Ortho-Clinical Diagnostics to Jointly Develop Diagnostic Products Based on Compugen Discovered Biomarkers
TEL AVIV, Israel--(BUSINESS WIRE)--June 8, 2005--Compugen Ltd. (Nasdaq:CGEN - News) announced today a collaboration agreement with Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, for the development and commercialization of immunoassay diagnostic markers. Under the agreement, Ortho-Clinical Diagnostics and Compugen will jointly develop diagnostic products based on biomarkers discovered by Compugen. Ortho-Clinical Diagnostics will have worldwide rights for commercialization, with Compugen receiving development milestones and royalties.
During the initial phase of the agreement, Ortho-Clinical Diagnostics will have the right to select up to nine biomarkers for development from Compugen's continuously growing portfolio, with the parties then collaborating on the initial clinical validation of the selected biomarkers. Under the agreement, successfully validated biomarkers will be developed into products and commercialized by Ortho-Clinical Diagnostics, with Compugen receiving milestone payments and license fees for each commercialized biomarker, in addition to revenue-based royalties.
The collaboration combines Compugen's unique discovery capability and existing candidate portfolio with Ortho-Clinical Diagnostic's global development and commercialization strengths. Compugen's discovery process relies on the comprehensive predictive analysis of the human proteome provided by the company's LEADS platform. The results of this analysis are utilized with a variety of discovery engines, each designed to identify novel proteins with specific desired characteristics from the vast number predicted by the discovery process.
Mor Amitai, President and Chief Executive Officer of Compugen, commented, "We are very pleased to enter this collaboration with Ortho-Clinical Diagnostics, one of the global leading diagnostics companies. This transaction is an important commercialization opportunity for us. We look forward to collaborating with Ortho-Clinical Diagnostics in this new arrangement, to identifying novel proteins with specific desired characteristics and to continue to provide valuable targets for commercialization both to our corporate partners as well as for our own therapeutic development programs."
http://biz.yahoo.com/bw/050608/85355.html?.v=1
Dubi
Compugen Names New President, CEO
Tuesday May 10, 10:45 am ET
Compugen Names Serono Executive Alex Kotzer As New President, CEO, Effective in September
NEW YORK (AP) -- Israeli drug and diagnostic company Compugen Ltd. said Tuesday it named Alex Kotzer as president and chief executive, effective Sept. 1, after his relocation to Israel.
Kotzer will replace Mor Amitai, who announced last October that he intends to resign from these positions before the end of 2005.
For the past 12 years, Kotzer has been employed by Swiss biotechnology firm Serono, and by its Israeli affiliate, InterPharm. Initially, he was president and CEO of InterPharm, until 1999, when he was promoted to vice president of the parent company and relocated to Switzerland.
Compugen shares rose 9 cents to $3.73 in morning trading on the Nasdaq.
http://biz.yahoo.com/ap/050510/compugen_ceo.html?.v=1
Midas
Compugen Appoints Alex Kotzer President and Chief Executive Officer as of September
Tuesday May 10, 7:00 am ET
TEL AVIV, Israel--(BUSINESS WIRE)--May 10, 2005--Compugen Ltd. (Nasdaq:CGEN - News) announced today the appointment of Alex Kotzer as President and Chief Executive Officer, effective September 1, 2005, after his relocation to Israel. Kotzer, whose most recent position was Vice President at Serono of Geneva, Switzerland, will replace current President and Chief Executive Officer Mor Amitai, Ph.D., who announced last October that he intends to resign from these positions before year end 2005.
ADVERTISEMENT
"Alex brings many years of relevant experience combined with a proven track record in managing biotech research, product development, and manufacturing in his previous positions at Serono and InterPharm," stated Martin Gerstel, Chairman of Compugen. "His background makes him ideal to lead Compugen, as we continue to expand and deepen our predictive research capabilities, and to advance the development and commercialization of our discovery engines as well as our diagnostic and therapeutic product candidates."
Gerstel added, "We are highly appreciative of Mor's efforts and accomplishments over the past decade. Compugen today is a world leader in advancing life science through the integration of mathematics and computational technologies with biology, and has established a unique position in the predictive discovery of potential therapeutic proteins and diagnostic biomarkers. These accomplishments, which are now providing us with ever-increasing potential for important medical contributions and substantial commercial success, have been made under Mor's guidance and leadership."
Kotzer commented, "I feel very privileged to join Compugen in the capacity of President and CEO at this important point in its development. Compugen's unique predictive approach to drug discovery, stemming from the integration of advanced mathematics and computational technologies with biology, sets it apart in philosophy and capabilities from other drug discovery and development companies. I look forward to the challenge of leading Compugen's outstanding team and contributing to the Company's continuing growth and future success."
For the past twelve years, Kotzer has been employed by Serono, a global biotechnology leader, headquartered in Switzerland, and by its Israeli affiliate, InterPharm. Initially he was President and Chief Executive Officer of InterPharm, which was at that time a public company. In 1999, he was promoted to Vice President of the parent company and relocated to Switzerland with responsibility for neurology and immunology product and process development, and for generating and executing the franchise's strategy. More recently, he was responsible for worldwide manufacturing of the active ingredients for all recombinant biological drugs of Serono. Kotzer has a B.Sc. in Chemical Engineering from the Technion, Haifa, Israel.
About Compugen
Compugen is a drug and diagnostic discovery company incorporating ideas and methods from mathematics, computer science, and physics into biology, chemistry and medicine. The Company's powerful predictive models and discovery engines are both advancing the understanding of important biological phenomena and enabling the discovery of numerous potential therapeutic products and diagnostic markers. The Company has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the Company; additional discoveries have been out-licensed for development. Among Compugen's customers and partners are leading pharmaceutical and diagnostic companies, such as Abbott Laboratories, Diagnostic Products Corporation, Novartis, and Pfizer. Compugen has established a small-molecule drug discovery affiliate - Keddem Bioscience, and an agricultural biotechnology affiliate - Evogene. For additional information, please visit Compugen's corporate Website at www.cgen.com.
http://biz.yahoo.com/bw/050510/105474.html?.v=1
Midas
BREAKOUT CONFIRMED breakout above 1.53, no resistance in area just above.
Type: Continuation breakout from single resistance.
Target: 1.72, +12.4%
http://www.stockconsultant.com/consultnow/basicplus.cgi?ID=sample&zz=5215&symbol=CGEN
This stock is currently trading alomost at cash value of 1.24/share.
http://biz.yahoo.com/p/c/cgen.html
Institutional Ownership 10%
http://yahoo.marketguide.com/MGI/HoldersReport.asp?target=%2Fstocks%2Fcompanyinf ormation%2Finstit%5Fowner&Ticker=CGEN
Over 87 million in assests (32mil is short term cash & equivalent)
http://yahoo.marketguide.com/MGI/mg.asp?target=%2Fstocks%2Fcompanyinformation%2F balancesheet%2Fqbalancestd&Ticker=CGEN
As with all Biotech’s the indicators are not the greatest. The MACD is below .10 nonetheless it is creeping its way towards the zero line (a buy signal for a lot of investors) The Chaikin Money Flow Indicator shows that the stock is not under accumulation although it does indicate that distribution has slowed during the last 2-3 weeks. Perhaps an indication of being undersold?
http://stockcharts.com/def/servlet/SC.web?c=CGEN,uu[h,a]daclyyay[dc][pb50!b200][ vc60][iUc20!La12,26,9]&pref=G
All in all I believe with such a high cash value relative to share price CGEN is a steal of a deal in this range. And like someone on this board allready mentioned all it takes is just one event, discovery, announcement in this industry and the share price goes through the roof.
Good Luck
riskyy
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
235
|
Created
|
08/22/02
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=CGEN
Compugen Ltd., an early stage drug and diagnostic discovery company, offers therapeutic and diagnostic biomarker product candidates for cancer, cardiovascular, and immune-related diseases in North America and Israel. It develops products using computer-based discovery platforms, as well as through analyzing DNA or RNA sequences, gene expression data, protein network data, data related to drugs in development, and drugs already being commercialized. The company?s validated discovery platforms include Splice Variant based Therapeutic Proteins, Nucleic-Acid Disease Markers, Protein Disease Markers, Monoclonal Antibody Targets, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, GPCR Therapeutic Peptide Ligands, New Indications, Disease-Associated Conformation Blockers, and Viral Peptides Discovery. Its therapeutic product candidates include CGEN-241, a splice variant of the MET receptor; CGEN-855, a peptide agonist of the FPRL1 GPCR receptor; CGEN-856 and CGEN-857, the MAS GPCR peptide agonists; CGEN-25007, an antagonist of the gp96 protein; CGEN-25008, a peptide antagonist of the Clusterin protein; CGEN-25009-4, an agonist peptide of the LGR7 receptor; CGEN-54, a splice variant of the MCP-1; CGEN-34, a splice variant of the peptide ANP; and CGEN-50001, a small molecule drug. The company?s diagnostic products include CGEN-144, a variant of the Troponin I biomarker; CGEN-438, a blood based biomarker for lung cancer; CGEN-6, a secreted splice variant protein; and CGEN-327, a biomarker for ovarian cancer. It also develops plant traits to the agbio industry through the use of a platform combining computational genomics, molecular biology, and breeding methods. Compugen has collaboration and license agreements with Roche; Siemens Healthcare Diagnostics, Inc.; Ortho-Clinical Diagnostics; Biosite; Teva Pharmacuetical Industries; Merck & Co.; Medarex, Inc.; and Bayer Schering Pharma AG. The company was founded in 1993 and is based in Tel Aviv, Israel.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |